About GSK plc
GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories.
The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
GSK operates in the Manufacturing | Pharmaceutical Products | approximately 90,100 employees | led by CEO Emma N. Walmsley.
Updated February 16, 2026
GSK plc earns a Buy rating from our quantitative model with a composite score of 74/100, ranking #17 among 7,333 U.S. stocks. The model sees a stock with an above-average factor profile — not without risks, but with enough quantitative support to warrant a constructive outlook.
The strongest dimension is value at 90/100, which places GSK in the top 10 percent of all stocks on this measure. stability at 89/100 provides secondary support. No single factor falls below the average threshold, which is a constructive sign.
Within the Manufacturing sector, GSK ranks 7th out of 50 peers, placing it in the 86th percentile. At $72.1 billion, the company is a well-established large cap.
Six-Factor Scorecard
Our model evaluates every U.S. stock across six independently measured dimensions. Each score represents a percentile rank — a score of 80 means the stock ranks higher than 80 percent of all companies on that factor.
Key Financial Metrics
Quality Analysis
GSK plc's quality score of 84/100 places it among the top profitability performers in the market. The quality factor evaluates margins, return on equity, return on assets, and earnings consistency — the fundamental building blocks of a durable business.
Return on equity of 22.6% exceeds the sector median of -2.0%. Gross margins of 71.2% reflect strong pricing power and competitive moats. Operating margins of 12.8% sit above the 3.0% sector average.
Net margins of 9.4% show the company is profitable, though not with exceptional efficiency.
Valuation Assessment
A value score of 90/100 puts GSK in the top 10 percent of all stocks on cheapness — suggesting the market is significantly underpricing the company's fundamentals. Key valuation metrics include a P/E ratio of 22.4x, an EV/EBITDA of 15.5x, a price-to-book of 5.7x, a price-to-sales of 1.8x. Deep value scores like this historically correlate with above-average forward returns, though they can also reflect legitimate concerns about business quality that the value factor does not capture.
Momentum & Timing
A momentum score of 72/100 shows GSK is trending above average, with its stock price outperforming the majority of the market. This is not explosive, meme-stock-style momentum — it is the gradual, fundamental-driven kind that tends to persist.
Revenue growth of 1.6% provides a moderate fundamental underpinning. A beta of 0.35 means GSK plc moves with less volatility than the market, which can be attractive for risk-conscious investors.
Our entry timing model currently signals Favorable, which warrants caution despite the price trend.
Risk Factors
No investment comes without risks, and honest analysis requires flagging them clearly:
- Leverage risk. A debt-to-equity ratio of 1.30 indicates significant leverage. In a rising rate environment or economic downturn, high debt loads can amplify losses and strain cash flow. Investors should monitor the company's ability to service its obligations.
- Model limitations. Quantitative models measure what is measurable — financial ratios, price trends, leverage — but cannot capture qualitative factors like management quality, competitive positioning, or pending litigation. This analysis should be supplemented with fundamental due diligence.
- Market regime risk. Factor-based strategies perform differently across market regimes. The current factor exposures that support GSK plc's rating may become headwinds if the macro environment shifts — for example, if interest rates move sharply or if sector rotation accelerates.
Bottom Line
GSK plc earns a Buy rating with a composite score of 74/100 and 4 out of 5 stars, ranking #17 among 7,333 stocks. The factor profile is constructive — not without blemishes, but with enough quantitative support to position GSK above the majority of the market.
Explore the full GSK analysis page for interactive factor breakdowns, or view the complete stock rankings.
Disclaimer: This article is generated by Blank Capital Research's quantitative model and is provided for informational purposes only. It does not constitute investment advice, a recommendation, or a solicitation to buy or sell any security. Past performance is not indicative of future results. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
